Active studies
Recruiting volunteers
Disease associated with glycoprotein antibody of myelin oligodendrocytes (mogad)
12 years or more
- Title: A multicenter phase III study, randomized, double-blind, placebo controlled to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of Satralizumab as monotherapy or in addition to base therapy in patients with disease associated with glycoprotein antibody of myelin oligodendrocytes (mogad)
Protocol: wn43194
pi: Dr. Douglas Sato
Sponsor: Roche
Study phase: Phase 3
Condition/disease: mogad
Medicine: Satralizumab
Criteria: 12 years or older (child, adult, elderly)
CLINICAL TRIALS Link: https: // clinicaltrials .gov/ct2/show/nct05271409? Term = wn43194 & draw = 2 & rank = 1
adult
- Title: a randomized, double-blind, placebo, multicenter, phase 3 study, main study with an open extension period to evaluate the effectiveness and safety of Rozanolixizumab in adult participants with disease associated with oligodendrocyte glycoprotein antibodies (MOG) of myelin
Protocol: mog001
pi: Dr. Douglas Sato
Sponsor: UCB Biopharma Srl
Study phase: Phase 3
Condition/disease: mogad
Medicine: rozanolixizumab
Criteria: 18 years to 89 years (adult, elderly)
Trials Clinical Link:
Multiple sclerosis
adult
- Title: remielinization and inflammation factors associated with treatment
with Natalizumab or other disease -modifying drugs for
Multiple Sclerosis (Remit-MS)
Protocol: does not apply
pi: Dr. Douglas Sato
Sponsor: Biogen
Study phase: does not apply
Condition/disease:
Medicine: Natalizumab / Teriflunomide / Dimethyl Fumarate / IFNβ / Acetate of Glattemer
Criteria: age between 18-45 years
Being starting treatment with Natalizumab, theriflunomide, dimethyl fumarate, IFNβ or glatirânt acetate, or starting in the last 30 days.
Clinical Trials Link: does not apply
Active (not recruiting)
Study of phase 3, randomized, double -blindness of efficacy and safety comparing SAR42168 with theriflunomide (Aubagio®) in participants with recurrent forms of multiple sclerosis - Gemini 2
Protocol: EFC16034
pi: Dr. Jefferson Becker
Sponsor: Sanofi Medley
Study phase: Phase 3
Condition/Disease: Multiple Sclerosis Refidive
Medicine: Tolebrutinib/Teriflunomide
Criteria:
ELECTIBLE AGES FOR STUDY: 18 YEARS TO 55 YEARS (ADULT)
Elegable Sexes for Study: All
Trials Clinical Link: https://clinicaltrials.gov/ CT2/Show/NCT04410991? Term = EFC16034 & Draw = 2 & Rank = 1
A multicenter, randomized, double -blind and controlled phase IIIB study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab in adults with Primary Progressive Multiple Sclerosis - Gavotte
Protocol: BN42083
pi: Dr. Jefferson Becker
Sponsor: Roche
Study phase: Phase 3
Condition/disease: Progressive Multiple Sclerosis
Medicine: Ocrelizumab
Criteria:
ELECTIBLE AGES FOR STUDY: 18 YEARS TO 55 YEARS (ADULT)
Elegable Sexes for Study: All
Clinical Trials Link:
https://clinicaltrias.gov/ct2/show/nct04548999?term=bn42083&draw=2&rank = 1
A 4 -year unique arm study to evaluate the efficacy and safety of ochrelizumab treatment in patients with progressive multiple sclerosis (consonance)
Protocol: mn39159
pi: Dr. Jefferson Becker
Sponsor: Roche
Study phase: Phase 3
Condition/disease: Progressive Multiple Sclerosis
Medicine: Ocrelizumab
Criteria:
Elegable Ages for Study: 18 years to 65 years (adult, elderly)
Elegable Sexes for Study: All
Clinical Trials Link:
https://clinicaltrials.gov/ct2/show/nct03523858?term=mn39159&draw=2&rank = 1
A unique arm, an open multicenter extension study to evaluate the effectiveness and safety of ocrelizumab in patients with multiple sclerosis previously inscribed in phase IIIB/IV clinical trials of F. Hoffmann-L-La Roche-Liberta
Protocol: mn39158
pi: Dr. Jefferson Becker
Sponsor: Roche
Study phase: Phase 3
Condition/disease: multiple sclerosis
Medicine: Ocrelizumab
Criteria:
Elegable Ages for Study: 18 years to 65 years (adult, elderly)
Elegable Sexes for Study: All
Clinical Trials Link:
https://clinicaltrials.gov/ct2/show/nct03599245?term=mn39158&draw=2&rank = 1
Effects of oral cladribine on remielinization and inflammation in patients with multiple sclerosis (claremi)
Title: Effects of oral cladribine on remielinization and inflammation in multiple sclerosis patients (claremi)
Protocol: ms700568_0128
pi: Dr. Douglas Sato
Sponsor: Merck Healthcare Kgaa
Study phase: Phase 4
Condition/disease: multiple sclerosis
Medicine: cladribina
Criteria: age between 18 and 55 years, including.
Clinical Trials Link: does not apply
A single -arm, open, extension and rollover multicenter study to evaluate the safety and long -term efficacy of ocrelizumab in patients with multiple sclerosis - (olero)
Protocol: mn43964
pi: Dr. Jefferson Becker
Sponsor: Roche
Study phase: Phase 3
Condition/disease: multiple sclerosis
Medicine: Ocrelizumab
Criteria:
ELECTIBLE AGES FOR STUDY: 18 years or older (adult, elderly)
Elegable Sexes for Study: All
Trials Clinical Link: https://clinicaltrials.gov/ CT2/Show/NCT05269004? TERM = MN43964 & Draw = 2 & Rank = 1
Effectiveness and safety of Natalizumab in Brazilian patients with recurring reiming multiple sclerosis in the real world - Reliance
Protocol: BR-TYS-11831
pi: Dr. Jefferson Becker
Sponsor: Biogen
Study phase: Phase 4
Condition/disease: recurrent reiming multiple sclerosis
Medicine: Natalizumab
Criteria:
Age older than or equal to 18 years on the starting date.
Clinical Trials Link: does not apply
*Observational Study
